E Ritz

Summary

Affiliation: CORE--Center for Outcomes Research
Country: Switzerland

Publications

  1. ncbi request reprint An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
    Andrew J Palmer
    Center for Outcomes Research, St Johanns Ring 139, CH 4056 Basel, Switzerland
    Nephrol Dial Transplant 18:2059-66. 2003
  2. ncbi request reprint Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 21:19-26. 2005
  3. ncbi request reprint Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
    Andrew J Palmer
    Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:1729-46. 2004
  4. ncbi request reprint Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S67-73. 2004
  5. ncbi request reprint What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S59-66. 2004
  6. ncbi request reprint Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S53-8. 2004
  7. ncbi request reprint Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S41-51. 2004
  8. ncbi request reprint Validation of the CORE Diabetes Model against epidemiological and clinical studies
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 20:S27-40. 2004
  9. ncbi request reprint The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 20:S5-26. 2004
  10. ncbi request reprint Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
    Andrew J Palmer
    CORE Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen Basel, Switzerland
    Diabetes Care 27:1897-903. 2004

Detail Information

Publications14

  1. ncbi request reprint An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
    Andrew J Palmer
    Center for Outcomes Research, St Johanns Ring 139, CH 4056 Basel, Switzerland
    Nephrol Dial Transplant 18:2059-66. 2003
    ..A simulation model was developed to project long-term cost consequences of the IDNT in Belgium and France...
  2. ncbi request reprint Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 21:19-26. 2005
    ....
  3. ncbi request reprint Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
    Andrew J Palmer
    Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:1729-46. 2004
    ..15%-points lower), reduced risk of major hypoglycaemic events (by 2%) and reduction in body mass index (BMI) (0.26 kg/m2) compared to protamine Hagedorn human (NPH) insulin-based basal/bolus therapy in type 1 patients...
  4. ncbi request reprint Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S67-73. 2004
    ....
  5. ncbi request reprint What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S59-66. 2004
    ..The aim of this study was to investigate the impact of stabilising beta-cell function on long-term outcomes in patients with type 2 diabetes...
  6. ncbi request reprint Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S53-8. 2004
    ....
  7. ncbi request reprint Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes
    Andrew J Palmer
    CORE Center for Outcomes Research, Binningen Basel, Switzerland
    Curr Med Res Opin 20:S41-51. 2004
    ....
  8. ncbi request reprint Validation of the CORE Diabetes Model against epidemiological and clinical studies
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 20:S27-40. 2004
    ..The aim of this study was to assess the validity of the CORE Diabetes Model by comparing results from model simulations with observed outcomes from published epidemiological and clinical studies in type 1 and type 2 diabetes...
  9. ncbi request reprint The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 20:S5-26. 2004
    ..The development of complications, life expectancy, quality-adjusted life expectancy and total costs within populations can be calculated...
  10. ncbi request reprint Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
    Andrew J Palmer
    CORE Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen Basel, Switzerland
    Diabetes Care 27:1897-903. 2004
    ..The aim of this study was to determine the most cost-effective time point for initiation of irbesartan treatment in hypertensive patients with type 2 diabetes and renal disease...
  11. ncbi request reprint An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
    A J Palmer
    Center for Outcomes Research, Basel, Switzerland
    J Hum Hypertens 18:733-8. 2004
    ....
  12. ncbi request reprint Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom
    Andrew J Palmer
    Center for Outcomes Research, Binningen Basel, Switzerland
    Clin Ther 26:304-21. 2004
    ....
  13. ncbi request reprint [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]
    A J Palmer
    Center for Outcomes Research, Basel, Schweiz
    Dtsch Med Wochenschr 129:13-8. 2004
    ..Aim of this study is to compare long-term consequences in costs and outcomes of IDNT treatment alternatives from the German health care system's perspective...
  14. ncbi request reprint [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]
    A J Palmer
    CORE Center for Outcomes Research, A Unit of IMS, Binningen, Switzerland
    Dtsch Med Wochenschr 131:1721-6. 2006
    ....